← Oncology Approval Tracker

FDA DECISION ·

Opdivo + Yervoy

nivolumab + ipilimumab · Bristol Myers Squibb

FDA approvalNew or expanded indicationMelanoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

The nivolumab and ipilimumab combination indication for unresectable or metastatic melanoma expanded to patients aged 12 or older.

LAMPGEN ANALYSIS

Why it matters

The paired supplements extended combined checkpoint blockade into adolescent melanoma.

What research teams should watch

Verify pediatric age and dosing and plan immune-related toxicity surveillance for the combination.

PRIMARY RECORDS

Sources